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Background: Mitogen-activated protein kinase kinase kinase3 (MAP3K3/MEKK3) was identified to be differentially
expressed in esophageal squamous cell carcinoma (ESCC) using cDNA microarrays by our laboratory. Here in we
determined the clinical significance of MEKK3 in ESCC.
Methods: Immunohistochemical analysis of MEKK3 expression was carried out in archived tissue sections from 93
ESCCs, 47 histologically normal and 61 dysplastic esophageal tissues and correlated with clinicopathological
parameters and disease prognosis over up to 7.5 years for ESCC patients.
Results: MEKK3 expression was significantly increased in esophageal dysplasia and ESCC in comparison with
normal mucosa (ptrend < 0.001). Kaplan Meier survival analysis showed significantly reduced median disease free
survival median DFS = 10 months in patients with MEKK3 positive ESCCs compared to patients with no
immunopositivity (median DFS = 19 months, p = 0.04). ESCC patients with MEKK3 positive and lymph node positive
tumors had median DFS = 9 months, as compared to median DFS = 21 months in patients who did not show the
alterations (p = 0.01). In multivariate Cox regression analysis, combination of MEKK3 overexpression and node
positivity [p = 0.015, hazard ratio (HR) = 2.082, 95% CI = 1.154 - 3.756] emerged as important predictor of reduced
disease free survival and poor prognosticator for ESCC patients.
Conclusions: Alterations in MEKK3 expression occur in early stages of development of ESCC and are sustained
during disease progression; MEKK3 in combination with lymph node positivity has the potential to serve as adverse
prognosticator in ESCC.
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Esophageal cancer is among the ten most common can-
cers worldwide and the sixth most common cause of
death from cancer [1,2]. The patients with this malig-
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reproduction in any medium, provided the orprogression [3]. Esophageal squamous cell carcinoma
(ESCC) is the major histological subtype of esophageal
cancer, being the second most common cancer among
males and the fourth most common cancer among fe-
males in India [4]. Despite advances in multimodality
therapy, due to late stage of diagnosis and poor efficacy
of treatment, the average 5-year survival rate for ESCC
patients is about 30% globally [5-7]. Development of bet-
ter preventive and diagnostic approaches as well as more
effective treatment modalities requires an in-depth un-
derstanding of molecular mechanisms implicated in the
complex process of esophageal carcinogenesis. Despitetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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management of ESCC in recent years there still remains an
urgent need for identification of novel molecular markers
to provide the clinician with useful information concerning
patient prognosis and possible therapeutic options [8-16].
In search of molecular markers our laboratory analyzed
global gene expression profiles of ESCCs, using commer-
cially available 19.1 k cDNA microarrays. MEKK3 cDNA
was one of the lead found to be overexpressed in ESCCs
[17]. These findings were verified using real-time quantita-
tive RT-PCR analysis that showed significant increase in
expression of MEKK3 transcripts in dysplasia and ESCCs
as compared to normal esophageal tissues [17].
The mitogen-activated protein kinases (MAPKs) are a
family of serine/threonine kinases that play important
regulatory roles in a wide variety of biological processes
[18]. Numerous mitogen-activated protein 3 kinases
(MAP3Ks) have been identified, including MEKK1,
MEKK2, MEKK3, MEKK4, tumor progression locus
2, and transforming growth factor-B-activated kinase 1,
that are activated by linear phosphorylation cascades.
MAP3Ks are emerging as important regulators of nu-
clear factor kappa B (NF-κB). MEKK3 is also called
MAP3K3, a kinase capable of activating both the ERK
and the stress-activated protein kinase cascades. It is
positioned upstream of SEK and MEK in the signalling
pathways and directly phosphorylates these enzymes.
Overexpression of MEKK3 has been reported to occur fre-
quently in ovarian cancer [19] that leads to increased
NF-κB activity and increased expression of cell survival
factors which ultimately contributes to their resistance
to apoptosis. In contrast, MEKK3 has been demon-
strated to be required for endothelium function but is
not essential for tumor growth and angiogenesis [20].
These reports clearly emphasize the need for in depth
investigations of the clinical relevance of MEKK3 in
human cancers. The aim of the present study was to
examine the clinical significance of MEKK3 in ESCC
and determine the correlation between MEKK3 ex-
pression and clinicopathological parameters of ESCC
patients. Further, we aimed to assess the prognostic
relevance of MEKK3 in ESCC patients.
Methods
Patients and clinicopathological data collection, tissue
specimens
The Institutional Human Ethics Committee of the All
India Institute of Medical Sciences (AIIMS), New Delhi,
India, approved this study prior to its commencement.
Tissue specimens were obtained by diagnostic or thera-
peutic procedures from patients with clinically defined
esophageal dysplasia (n = 61) attending the Outpatient
Clinic of the Departments of Surgical Disciplines and
Gastrointestinal Surgery, AIIMS. Tissue specimens werealso collected from 93 ESCC patients undergoing cura-
tive cancer surgery during the period 2005–2010, after
obtaining the patients’ written consent. Wherever pos-
sible, non-malignant tissues were taken, each from a site
distant from the surgically resected ESCC. Non-malignant
esophageal tissues were also collected from the patients
attending the Endoscopy clinic in the Outpatient Depart-
ment of Gastroenterology, after obtaining the patients’
written consent. Taken together, these 47 non-malignant
esophageal tissues with histological evidence of normal
epithelia constituted the normal group. After excision, tis-
sues were immediately snap-frozen in liquid nitrogen and
stored at −80°C in the Research Tissue Bank till further
use; one part of the tissue was collected in 10% formalin
and embedded in paraffin for histopathological and
immunohistochemical analyses. Histologically confirmed
esophageal normal epithelia, dysplasia, and ESCC as re-
vealed by hematoxylin and eosin (H&E) staining were
used for immunohistochemistry [21,22]. Patient demo-
graphic, clinical, and pathological data were recorded in a
pre-designed Performa as described previously to establish
a clinical database [21,22]. The information documented
included clinical TNM staging (tumor, node, and metasta-
sis based on the Union International Center le Cancer
TNM classification of malignant tumors 2002), site of the
lesion, histopathological differentiation, age and gender.
All the ESCC tissues analyzed in this study had more than
80% tumor cells in H&E sections.
Follow-up study
Eighty two of 93 ESCC patients who underwent treatment
from 2005–2010 could be investigated and evaluated in
the esophageal cancer follow-up clinic at regular time in-
tervals, while 11 patients did not report in the follow up
clinic. Survival status of the ESCC patients was verified
and updated from the records of the Tumor Registry, De-
partment of Gastrointestinal Surgery, AIIMS, as of June
2013. ESCC patients were monitored for a maximum
period of 7.5 years. Disease-free survival time is defined as
the time from completion of primary treatment till the pa-
tient showed any clinical and radiological evidence of local
or regional disease, or distant metastasis at the time of the
last follow-up of patients monitored in this study. Thirty
one patients who did not show recurrence were alive until
the end of the follow-up period. Only disease-free survival
(expressed as the number of months from the date of sur-
gery to loco-regional relapse/death) was evaluated in the
present study, as the number of deaths due to disease pro-
gression did not allow a reliable statistical analysis.
Immunohistochemistry
Paraffin-embedded sections (5 μm) of human esophageal
histological normal (n =47), dysplasia (n = 61) and ESCC
(n = 93) were collected on gelatin-coated slides. In brief,
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gradient alcohol, and pre-treated in a microwave oven
for 10 min at 800 W and 5 min at 480 W in Citrate
buffer (0.01 M, pH = 6.0) for antigen retrieval. The sec-
tions were incubated with hydrogen peroxide (3% v/v)
in methanol for 30 min to quench the endogenous
peroxidise activity, followed by blocking with 1% bo-
vine serum albumin (BSA) to preclude non-specific
binding. Thereafter, the slides were incubated with
rabbit polyclonal anti-MEKK3 antibody (0.5 mg/ml,
sc-28769, Santa Cruz Biotechnology, San Diego, CA)
for 16 h at 4°C. The primary antibody was detected
using the streptavidin-biotin complex with the Dako
LSAB plus kit (Dako Cytomation, Glostrup, Denmark)
and diaminobenzidine as the chromogen as described
previously [23]. In the negative control tissue sec-
tions, the primary antibody was replaced by isotype
specific non-immune mouse IgG. A section from
breast cancer tissue was used as a positive control in
each batch of immunohistochemistry.
Evaluation of immunohistochemical staining
Each tissue section was evaluated for MEKK3 immuno-
staining using a semi-quantitative scoring system forFigure 1 Immunohistochemical analysis of MEKK3 in esophageal tissues
and ESCC were stained using anti-MEKK3 polyclonal antibody as described in t
immunostaining; (ii) dysplasia depicting nuclear and cytoplasmic MEKK3 immu
and nuclear staining in tumor cells; (iv) ESCC section showing cytoplasmic MEK
isotype specific IgG replacing the primary antibody showing no MEKK3 immunboth staining intensity and the percentage of positive
epithelial cells [22]. For MEKK3 protein expression, sec-
tions were scored as positive if epithelial cells showed
immunopositivity in the nucleus/cytoplasm when ob-
served independently by three of us (MRH, RS, SDG),
who were blinded to the clinical outcome (the slides were
coded and the scorers did not have prior knowledge of the
local tumor burden, lymphonodular spread, and grading
of the tissue samples). The tissue sections were scored
based on the% of immunostained cells as: ≤10% = 0; 11–
30% = 1; 31–50% = 2; 51–70% = 3 and > 70% = 4. Sections
were also scored semi-quantitatively on the basis of stain-
ing intensity as negative = 0; mild = 1; moderate = 2; in-
tense =3. Finally, a total score was obtained by adding the
scores of percentage positivity and intensity. The scoring
by the three observers was discrepant in about 5% cases
and a consensus on the final result was reached by re-
evaluation of these slides and discussion. Based on sensi-
tivity and specificity values for MEKK3, a total score cut-
off value of 3 was defined as MEKK3 immunopositivity.
Statistical analyses
The immunohistochemical data were subjected to statis-
tical analyses using the SPSS 13.0 software (Chicago, IL).. Paraffin-embedded sections of histologically normal mucosa, dysplasia,
he Methods section. (i) Normal esophageal mucosa showing no MEKK3
nostaining in epithelial cells; (iii) ESCC illustrating both intense cytoplasmic
K3 immunostaining; (v) ESCC used as a negative control incubated with
ostaining in tumor cells ((i-v) original magnification x 200).
Table 1 Immunohistochemical analysis of MEKK3 protein in esophageal tissues and relationship with
clinicopathological parameters
Clinicopathological features Total cases (N) Cytoplasmic/nuclear positivity n (%) P-value OR (95% CI)
Normal 47 10 (21)
Dysplasia 61 34 (55.7) <0.001 4.6 (1.9-11.0)
ESCC 93 63 (67.7) 0.001 7.77 (3.41-17.7)
Age (years)
<54 43 30 (69.8) 0.825 0.84 (0.35-2.01)
> = 54 50 33 (66)
Gender
Male 62 40 (64.5) 0.481 1.58 (0.60-4.12)
Female 31 23 (74.2)
Tumor stage
(T1 + T2) 10 6 (60.0) 0.722 1.46 (0.38-5.62)
(T3 + T4) 83 57 (68.7)
Nodal status
N0 27 19 (70.4) 0.81 0.84 (0.31-2.22)
N1 66 44 (66.7)
Histopathology
WDSCC 30 20 (66.7) 0.61 0.6 (0.20-1.87)
MDSCC 48 33 (68.7)
PDSCC 15 10 (66.7)
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using receiver operating characteristic (ROC) analyses.
The positive predictive value (PPV) describes the pro-
portion of the correctly classified cases. A total score
cut-off value of 3 was defined as MEKK3 immunoposi-
tivity for statistical analyses. The relationships betweenFigure 2 Receiver operating curve (ROC) analysis for MEKK3 expressio
versus Cancer.MEKK3 protein expression and clinicopathological pa-
rameters were tested using Chi-Square and Fischer’s exact
test. Two-sided p values were calculated and p < 0.05 was
considered to be significant. Similarly, PPV was calculated
for esophageal dysplasia and ESCC with respect to normal
tissues. The correlation of MEKK3 staining with patientn in esophageal tissues. (a) Normal versus Dysplasia; (b) Normal
Table 2 Biomarker analysis of MEKK3 expression in
esophageal tissues
MEKK3 Sensitivity Specificity PPV AUC
Normal vs. dysplasia 55.56 78.72 60.0 0.68
Normal vs. ESCC 52.46 78.72 86.3 0.80
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survival data with Kaplan-Meier plots. Multivariate ana-
lysis was carried out using Cox regression model [24].
Results
Immunohistochemical analysis of MEKK3 expression in
esophageal normal, dysplasia and cancer
To determine the clinical significance of MEKK3 protein
in ESCC, its expression was analyzed in clinical speci-
mens from, histologically normal esophageal tissues, dys-
plasia, and ESCC using a specific anti-MEKK3 antibody
by immunohistochemistry. Of the 47 normal tissues ana-
lyzed, 37 (79%) cases did not show detectable MEKK3
immunostaining in nucleus/cytoplasm of epithelial cells
[Figure 1 (i)]; moderate staining was observed in differ-
entiated epithelial cells in 10/47 (21%) normal tissues.
Chi square trend analysis showed significant increase in
MEKK3 expression (cytoplasmic/nuclear) in tissues ob-
tained from different stages of esophageal tumorigenesis
(normal, dysplasia and ESCC; Table 1, ptrend < 0.001). Not-
ably, significant increase in cytoplasmic/nuclear localization
of MEKK3 was observed in 34 of 61 (55.7%) dysplasia cases
(p < 0.001, odd’s ratio (OR) = 4.6, 95% CI = 1.9-11.0)
compared to normal esophageal tissues [Table 1 and
Figure 1 (ii)]. Similar localization pattern of MEKK3Figure 3 Evaluation of MEKK3 overexpression as a prognostic marker
disease-free survival: (a) Median time for disease-free survival (DFS; no recu
(shown with solid line) DFS was 10 months and was significantly reduced
staining (p = 0.005; median DFS = 19 months, shown with dotted line); (b)
patients showing increased MEKK3 expression and lymph node positivity (s
as compared to patients with ESCC that showed no or mild immunostainin
dotted line).immunostaining was observed in ESCC as well [Figure 1
(iii, iv)]. Sixty three of 93 (67.7%) ESCCs showed cyto-
plasmic/nuclear localization of MEKK3 in tumor cells
as compared to the normal tissues (p < 0.001, OR = 7.77,
95%, CI = 3.41-17.7). However, no significant correla-
tions were observed between clinicopathological param-
eters of ESCC and MEKK3 expression (Table 1). No
immunostaining was observed in ESCC tissue sections
used as negative controls where the primary antibody
was replaced by isotype specific IgG (Figure 1v). Re-
ceiver Operating Characteristic (ROC) analysis was used
to determine the area-under-the-curve (AUC) - 0.68
and 0.80, with sensitivity of 55.56% and 52.46% for dys-
plasia and ESCC respectively, and specificity of 78.72%
for both (Figure 2A and B; Table 2).
MEKK3 overexpression as a prognostic marker for ESCC
Kaplan–Meier survival analysis showed significantly
reduced disease-free survival (median disease free sur-
vival = 10 months) in ESCC patients harbouring in-
creased MEKK3 expression compared with the patients
showing no nuclear/cytoplasmic MEKK3 immunostain-
ing (p = 0.04, median DFS = 19 months), (Figure 3a).
Notably, ESCC patients showing nodal positivity and
MEKK3 overexpression had significantly reduced me-
dian DFS = 9 months in comparison node negative
patients with low MEKK3 expression (median DFS =
21 months; range 1–90 months; p = 0.01) (Figure 3b).
Cox regression analysis was carried out to determine the
prognostic potential of MEKK3 overexpression for ESCC
in comparison with the other clinical parameters - nodal
status (Table 3). MEKK3 overexpression in combinationin ESCC. Kaplan–Meier estimation of cumulative proportion of
rrence/metastasis) in patients showing increased MEKK3 expression
as compared to patients with ESCC that showed no or mild immuno-
Median time for disease-free survival (DFS; no recurrence/metastasis) in
hown with solid line) DFS was 9 months and was significantly reduced
g (median DFS = 21 months; range 1–90 months p = 0.01; shown with
Table 3 Correlation of overall survival with clinicopathological parameters and MEKK3 expression: multivariate
analysis
Clinico- pathological parameter Kaplan Meier Survival analysis Multivariate Cox regression analysis Hazard ratio (95% CI)
Un-adjusted p-value Adjusted p-value
MEKK3 and lymph node positivity 0.010 0.015 2.082 (1.154- 3.756)
MEKK3 Staining 0.040 0.379
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prognostic marker for ESCC (p = 0.015 HR = 2.082, 95%
CI = 1.154- 3.756) (Table 3).
Discussion and conclusions
Our study demonstrated significant increase in MEKK3
expression in esophageal dysplasia and ESCC in compari-
son with normal esophageal tissues. Further, correlation of
MEKK3 expression with clinical outcome showed that
overexpression of this protein is associated with shorter
disease free survival and thus poor prognosis of ESCC pa-
tients. Our findings are important in view of the fact that
studies on molecular analysis of esophageal dysplasia are
very limited, often because these patients do not seek
medical attention due to small size of the lesions that do
not pose any serious clinical problems, or patients avoid
endoscopic examination. Therefore, there are no estab-
lished biomarkers that can be used in clinics routinely in
early stages of the disease. The histological evidence of
dysplasia is insufficient to identify lesions that are at high
risk of cancer development. Hence, overexpression of
MEKK3 observed in dysplastic lesions is an important
finding of our study that underscores its potential as an
early marker. Notably, MEKK3 protein was detected in
the distant dysplastic esophageal tissues in patients with
ESCC, while no detectable expression was observed in the
matched histologically normal esophageal epithelia distant
from the tumors. The presence of MEKK3 in early pre-
neoplastic lesions, and localized expression of MEKK3 in
areas of high proliferative activity support the hypothesis
that alteration in MEKK3 expression is an early event in
esophageal tumorigenesis.
The hallmark of the study was the detection of MEKK3
protein in endoscopic biopsies of esophageal epithelial
dysplasia, suggesting its potential for development as an
early biomarker. We are cognizant of the fact that limita-
tions of our study are the small size of dysplasia cases in-
vestigated and lack of follow-up data of patients with
dysplasia. Nevertheless, to our knowledge this is the first
study demonstrating overexpression of MEKK3 in early
stage prior to development of frank malignancy, as well as
in ESCC, that offers an opportunity for early detection
and intervention for effective management of this dis-
ease, which otherwise has poor prognosis (overall 5-year
survival ranges from 15-25%) particularly when detectedin late stages [25]. Our findings warrant long term lon-
gitudinal follow-up studies of patients with esophageal
dysplasia that go on to develop ESCC, to establish a
possible link between MEKK3 overexpression and risk
of cancer development. Nevertheless, in view of the lack
of availability of molecular markers for early diagnosis
of ESCC having insidious symptomatology, our findings
are of potential clinical relevance. The molecular basis
of MEKK3 overexpression in esophageal dysplasia is
supported by the recent review on the role of cancer–
related inflammation in ESCC [26].
The significant increase in MEKK3 expression ob-
served in ESCC (67.7% cases) as compared to normal
esophageal tissues is another important finding of our
study suggesting that accumulation of MEKK3 may be
linked to increased risk of malignant transformation and
might serve as a marker to identify the high-risk lesions.
Notably, our study suggested the clinical significance of
MEKK3 overexpression as a predictor of poor prognosis
of ESCC. To our knowledge this the first report of
MEKK3 as a biomarker of prognostic relevance in ESCC.
The functional significance of MEKK3 protein in esopha-
geal tumorigenesis remains to be determined. We specu-
late that with a growing understanding of the role of
MEKK3 in cell migration, invasion and proliferation path-
ways, the potential of MEKK3 as a therapeutic target for
the treatment of cancer should be the subject of future
studies. In support of our findings MEKK3 overexpression
has been reported in ovarian cancer as compared to nor-
mal ovarian epithelial cells [19].
In conclusion, this study provides evidence of MEKK3
overexpression in dysplastic esophageal epithelium as
well as in ESCC, suggesting that MEKK3 expression is
altered in early stages and sustained in esophageal
tumorigenesis. These findings are of immense clinical
relevance in view of the fact that early detection of
ESCC is severely hampered by the paucity of molecular
markers for diagnosis of this aggressive malignancy in
initial stages. MEKK3 overexpression is a predictor of
poor prognosis of ESCC. Furthermore, increased accu-
mulation of MEKK3 in ESCC as compared to dysplastic
lesions warrants a large-scale longitudinal study of pa-
tients with dysplasia to evaluate its potential as a deter-
minant of increased risk of progression to cancer and as
a marker for recurrence of ESCC.
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